Takeda Pharmaceutical

Recruiting a foreign CEO: Christophe Weber and the shift to global management (2014)

Key decision·2014· Takeda Pharmaceutical — the full company history →

A succession that severed management from nationality

The heart of this decision was that, to govern a business it had spread across the world, Takeda stepped into the internationalization of management itself. It had extended its operations globally by acquisition while failing to grow, from within, the executives to bind them together. Hasegawa and the board chose not to wait on in-house development but to bring in from outside a foreigner who knew the market well. Opening a management that founding family and lifers had carried for more than two centuries into a single post held regardless of nationality is what marks the character of this succession.

Recruiting from outside, however, sped the internationalization of the business while deferring the time it would take to raise the next chief at home. The Weber regime ran to about twelve years — a long tenure not easily changed even when results stalled. That Takeda entrusted the next CEO, in 2026, to another foreigner in Julie Kim is the flip side of the same fact. The fruit of globalization, and the unmet task of growing management talent in-house — the recruitment of a foreign chief left both behind at once.

Revenue and net margin, FY2009–FY2019

Revenue in ¥ bn (bars) and net margin in % (line), for the years around the decision. Shaded columns are FY2014 onwards — after it was taken.

Source: securities reports

Read the full dossier in Japanese →

The Japanese edition carries the complete record of this decision — the situation that forced it, the options weighed, what actually followed, and the sources behind every claim.

Other key decisions at Takeda Pharmaceutical


Yen amounts are converted at the average rate of each figure’s own year — not today’s rate; the revenue chart is shown in yen. Exchange rates & sources — the full ¥/US$ table →


Disclaimer

  • This page is provided for general information only and is not investment advice, nor a recommendation to buy or sell any security.
  • Figures are compiled independently and include our own estimates, approximations and machine-processed data; we make no warranty as to their accuracy or completeness.
  • Sources are primarily each company’s securities reports and other public filings, but errors and omissions may remain.
  • Any use of this information is at the reader’s own risk. Past performance does not indicate future results.
  • Company names, logos and other marks belong to their respective owners.

Data API

Takeda Pharmaceutical’s history, financials, executives and shareholders are published as static JSON — no key, plain GET. Full specification →

Method Endpoint Returns
GET /api/companies.json All companies
GET /api/4502/manifest.json Resource index
GET /api/4502/history.json History overview
GET /api/4502/timeline.json Chronology
GET /api/decisions.json All management decisions (index)
GET /api/4502/decisions.json Management decisions (index)
GET /api/4502/decisions/{slug}.json One decision (full dossier)
GET /api/4502/executives.json Executives
GET /api/4502/shareholders.json Major shareholders
GET /api/4502/financials.json Financial statements
GET /api/4502/financials-longterm.json Long-term results
GET /api/4502/segments.json Business segments
GET /api/4502/regions.json Sales by region
GET /api/4502/workforce.json Workforce